How many insider trades does FilingIQ track for CGEN?

FilingIQ tracks 41 Form 4 insider transactions for CGEN (COMPUGEN LTD), covering filings from Mar 26, 2026 onwards. 41 of those were filed in the last 90 days.

Are CGEN insiders net buyers or net sellers?

Across the full Form 4 history for CGEN, 0 transactions (0%) were open-market purchases and 11 (27%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CGEN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CGEN in?

COMPUGEN LTD (CGEN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $188.99M.

CGEN insider trading

NasdaqCM Healthcare

COMPUGEN LTD — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 27%

Market cap

$188.99M

About COMPUGEN LTD

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Company website: cgen.com

CGEN insider activity at a glance

FilingIQ has scored 41 insider transactions for CGEN since Mar 26, 2026. The most recent filing in our index is dated Apr 24, 2026.

Across the full history, 0 open-market purchases and 11 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live CGEN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CGEN?: FilingIQ tracks 41 Form 4 insider transactions for CGEN (COMPUGEN LTD), covering filings from Mar 26, 2026 onwards. 41 of those were filed in the last 90 days.
Are CGEN insiders net buyers or net sellers?: Across the full Form 4 history for CGEN, 0 transactions (0%) were open-market purchases and 11 (27%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CGEN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CGEN in?: COMPUGEN LTD (CGEN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $188.99M.

Methodology & sources

Every CGEN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.